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Abstract: Soy isoflavones have been extensively used for menopausal symptoms 
and prevention of hormone-related cancer, osteoporosis and cardiovascular diseases. 
Commercially available forms of isoflavones include supplements, capsules and 
tablets. However, the non-standardization of soy isoflavones extracts and different 
dissolution profiles of these solid dosage forms highlight the need of additional 
studies on the development of well characterized pharmaceutical dosage forms of 
isoflavones. In this work, immediate release oral tablets of soy isoflavones were 
obtained and evaluated. Genistein and daidzein, were the main constituents of the 
dried soy extract. Preparation of the tables was accomplished in a rotary tableting 
machine following either a dry mixture for direct compression or wet granulation 
with different excipients. Powder, granules and tablets were evaluated for several 
parameters, including flow properties, Carr and Hausner indexes, hardness, friability, 
disintegration time and drug release profile. Also, a fast and validated HPLC 
analytical method for both genistein and daidzein was developed. Formulations 
containing sodium croscarmellose and sodium dodecyl sulfate resulted in better 
flowability as indicated by the flow rate and angle of repose, faster disintegration 
time and immediate release dissolution profile. 
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Introduction
 Scientific developments have increased the 
interest in the use of herbal products as therapeutic 
agents (Silva et al., 2012). From a vast number of plant 
constituents, isoflavones are among the most studied 
due to their estrogen-like activity without common side 
effects from hormonal therapies (César et al., 2006). 
Additionally, isoflavones have been extensively used 
for menopausal symptoms and prevention of hormone-
related cancer, osteoporosis and cardiovascular diseases 
(Howes et al., 2000; Ferrari, 2009). 
 Isoflavones have been widely used and 
became commercially available as over-the-counter 
(OTC) supplements, capsules and tablets. The 
extensive advantages of oral dosage forms, such as 
convenience and compliance, made isoflavone tablets 
very popular for postmenopausal treatments (Shen et 
al., 2010). However, the development of solid dosage 
forms using plant raw materials is not an easy task 
since herbal materials exhibit poor flowability and 
low compressibility (Palma et al., 2002). In addition, 
isoflavones most frequently found in soybean extracts 
(genistein, daidzein, genistin, daidzin and glycitin) are 
poorly water-soluble with low membrane permeability, 
which is considered a challenge for the development of 
oral dosage forms (Shen et al., 2010).
 Clinical trials with the commercial dosage 
forms containing isoflavones demonstrated a large 
variability of therapeutic and side effects originated 
from these preparations, questioning the reliability of 
the efficacy and safety of these phytomedicines (Palma 
et al., 2002). These variations could be caused mainly 
by the non-standardization of soy isoflavones extracts 
(Setchell et al., 2005; Campos et al., 2006) and different 
dissolution profiles of the solid dosage forms. 
 In spite of the wide use isoflavones as 
phytomedicines, few studies related to the development 
of isoflavone tablets have been conducted. Until 
recently, the majority of the concerns have been focused 
on the standardization extract, but little attention has 
been given to the development of pharmaceutical 
forms. In the present work, a systematic investigation 
of formulation and technological parameters on soy 
isoflavone tablets was performed. Tablets with different 
disintegrating agents, surfactants and diluents were 
obtained either by direct compression or wet granulation, 
and the influence of these techniques was evaluated. 
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Additionally, an analytical method for genistein and 
daidzein was developed and validated according to 
ICH guidelines in order to monitor the quality of the 
tablets, their stability and dissolution profile for these 
main constituents of the soybean extract.
Materials and Methods 
Materials
 Dried soy extracts (≥40% of total isoflavones) 
were produced by Sichuan Xieli Pharmaceutical 
(China) and distributed by PharmaNostra (Anápolis, 
Brazil, batch number 08010079A). According to 
the manufacturer, the total content of the glycosides 
daidizin and genistin was, combined, 3.25% (w/w). 
Daidzein and genistein content were 32.79% (w/w) 
and 10.75% (w/w), respectively. Analytical standards 
of daidzein (min. 99%) and genistein (min. 99%) were 
purchased from LC Laboratories (Woburn, MA, USA).
 Microcrystalline cellulose PH-102 and sodium 
croscarmellose (CROS) were purchased from Blanver 
Farmoquímica Ltda (São Paulo, Brazil). Crospovidone 
(CROS-POV) (Polyplasdone XL®, particle size 100-
130 μm and Polyplasdone XL-10, particle size 30-50 
μm) was kindly donated by ISP (São Paulo, Brazil). 
Hydroxypropyl methylcellulose (Opadry YS-1-7006®) 
was purchased from Colorcon Inc. (São Paulo, Brazil). 
Titanium dioxide was from Huntsman (California, 
USA). Magnesium stearate was from Shengzhou 
Light Ind. Factory (China). Talc, anhydrous dicalcium 
phosphate and lactose M200 were from Indukern 
(Barcelona, Spain). Colloidal silicon dioxide was 
purchased from Evonik Industrie (Germany). Sodium 
dodecyl sulfate (SDS) was purchased from Vetec (São 
Paulo, Brazil). Acetonitrile, methanol, and acetic acid 
were HPLC grade and were purchased from JT Baker 
(Phillipsburg, NJ, USA). Water was purified using a 
Milli-Q system (Millipore®, Billerica, MA, USA) with 
a 0.22 μm pore end filter.
Methods
 Genistein and daidzein quantitation by High 
Performance Liquid Chromatography
 Chromatographic separation of genistein and 
daidzein was achieved with an HPLC system consisting 
of a quartenary pump (ProStar 240, Varian, Palo Alto, CA, 
USA), autosampler (ProStar 410, Varian, Palo Alto, CA, 
USA) and UV detector (ProStar 310, Varian, Palo Alto, CA, 
USA). Separation was achieved in an Agilent ChromSpher 
C18 column (150 x 4.6 mm, 5 μm) with column temperature 
of 30 °C. The mobile phase was methanol (0.1% acetic 
acid):water (0.1% acetic acid):acetonitrile 64:32:4 (v/v/v). 
Flow-rate was 0.7 mL/min, injection volume was 10 μL and 
UV detection was carried out at 254 nm. Data acquisition 
was performed using a Galaxie Chromatography Data 
System Software. The method was validated in accordance 
to ICH guidelines (ICH, 2003). 
 Analysis of dried soy extract 
 Samples of dried soy extract were analyzed 
using the validated HPLC method described above. 
The amount of genistein and daidzein was determined 
without previous acidic hydrolysis. Ten miligrams 
of dried soy extract were weighted and added to a 
volumetric flask with 50 mL methanol. The solution 
was sonicated for 20 min, diluted to obtain a final 
concentration of 100 μg/mL, filtered and analyzed by 
HPLC. 
 For the hydrolysis procedure, 50 mg of dried 
soy extract were mixed with 3.0 M HCl ethanolic 
solution in a volumetric flask (100 mL). The mixture 
was heated (60 °C) and refluxed for 40 min. After that, 
samples were diluted to obtain a final concentration of 
100 μg/mL, filtered and analyzed by HPLC. 
 Development of solid dosage forms containing 
dried soy extract
 Tablets containing dried soy extract were 
produced by either wet granulation or direct compression 
techniques. Table 1 shows the percent composition of 
the tablets prepared with soy extract. The influence of 
the type and concentration of the disintegrant agent, as 
well as the presence of the surfactant were determined 
for the wet granulation formulations (Table 1). The 
granulation was achieved by mixing the plant extract 
and the adjuvants previously sieved (sieve aperture 
1.0 mm); then, 300 g of the resulting mixture were 
agglomerated by adding 90 mL of an ethanolic solution 
containing povidone 3% (w/v). After the addition of 
the liquid, the wet mass was passed through a 2 mm 
sieve in a conical mill (Stinfer, model GS Lab, São 
Paulo, Brazil). The granules were dried in an oven at 
40 °C until the relative humidity reached 5% (w/w). 
After that, dry granules were calibrated in a 1.4 mm 
sieve and mixed with colloidal silicon dioxide (0.5%) 
and magnesium stearate (1.5%) using a V-mixer for 5 
min at 10 rpm. A rotary tablet machine (Lawes model 
08-PSC MANU, São Bernardo do Campo, Brazil) was 
fed with this final mixture and circular tablets (9 mm 
width) with 300 mg weight were obtained.
 For the preparation of tablets by direct 
compression (DC), mixtures of dried soy extract (50%) 
with the adjuvants (Table 1) were obtained in a V-mixer 
(10 min at 10 rpm). Blends were directly compressed on 
a rotary tablet machine (Lawes model 08-PSC MANU, 
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São Bernardo do Campo, Brazil) using 9 mm circular 
punches and dyes.
 Tablet coating
 Tablets were coated using a conventional pan 
coater (Lawes, São Bernardo do Campo, Brazil) and a 
two-fluid coaxial type atomization device (DeVilbiss, 
Glendale Heights, USA) with an insert diameter of 1.4 
mm. The coating suspension was prepared by dissolving 
the 3.0% (w/v) hydroxypropyl  methylcellulose 
(Opadry® YS-1-7006), 1.0% (w/v) polyethyleneglycol 
6,000, 2.0% (w/v) titanium dioxide and talc and 0.05% 
(w/v) red dye. Five hundred milliliters of the ethanolic 
dispersion were applied to the tablets’ surface after 
tablet bed temperature reached 40 °C by insufflation of 
heated air.
 Characterization of powder and granules
 The flowability of soy isoflavone extract, 
powder mixtures and granules was characterized 
by measuring flow rate (Erweka GTB, Frankfurt, 
Germany), angle of repose (Erweka GTB, Frankfurt, 
Germany), Carr and Hausner indexes. 
 Flow rate and angle of repose were determined 
by pouring 100 g of the sample through a funnel (15 
mm diameter orifice). Automatic measurement of flow 
rate was obtained in an Erweka GTB instrument. Angle 
of repose was determined by measuring the slope of the 
heap of powders or granules that fell from the funnel to 
a flat surface.
 Carr and Hausner indexes were determined 
from tapped and bulk density data. Bulk density was 
determined by adding 100 g of powder to a graduated 
cylinder (250 mL). Tapped density was measured after 
tapping 500 times the cylinder (Erweka SVM 203, 
Frankfurt, Germany) according to USP 35. Equations 
1 and 2 were employed to calculate Carr and Hausner 
indices:
  (1)
   (2)
 
 Water content of the powder and granules was 
gravimetrically determined using an infrared scale 
(Gehaka, São Paulo, Brazil). Soy extract, powder 
mixture or granules were added to the scale plate and 
dried at 105 °C until constant weight.
 Characterization of tablets containing dried 
soy extract
 The physical properties of the tablets were 
evaluated according to the 4th edition of the Brazilian 
Pharmacopeia (1988). To study weight variation, 
twenty tablets of each formulation were weighed using 
an electronic scale (Sartorius digital balance TE-214S, 
NY, USA). Thickness and hardness were measured 
individually from twenty tablets using a portable digital 
tablet tester (Nova Ética, model 298 DGP, Vargem 
Grande Paulista, Brazil). Friability was determined 
from twenty tablets by measuring the average weigh lost 
after 100 revolutions in a friabilometer (model 300.1, 
NOVA ÉTICA, São Paulo, Brazil). Disintegration was 
determined in a disintegration apparatus (model 301/
AC, NOVA ÉTICA, São Paulo, Brazil), with a water 
bath operating at 37±1 ºC. Six tablets were individually 
placed in the apparatus cylinders. Disintegration 
time was recorded when the last of the six units was 
completely disintegrated.
 In vitro drug release studies (Dissolution test)
 To properly design the dissolution assay, 
genistein and daidzein solubilities were evaluated in 
several different media: water, sodium acetate buffer 
Table 1. Composition of tablets containing dried soy extracts.
Formulations
Amount of raw material in different formulations (%)a
Lactoseb Dicalcium phosphateb
Sodium 
croscarmellose 
(CROS)c
Crospovidone 
(CROS-POV) XLc
Crospovidone 
(CROS-POV) 
XL-10c
Sodium dodecyl 
sulfate (SDS)d
Colloidal 
silicon dioxidee
CROS 26.98 - 3.00 - - - 0.50
CROS-SDS 24.98 - 3.00 - - 2.00 0.50
CROS-POV 25.98 - - 2.00 - 2.00 0.50
CROS-POV-10 25.98 - - - 2.00 2.00 0.50
DC - 29.98 - - - - 1.00
aThe other components were added to all formulations in the same amounts (soy extract (50%), diluent microcrystalline cellulose (15%), 
lubricant magnesium stearate (1.5%) and antioxidant butylhydroxytoluene (0.02%)); bdiluent; cdisintegrant; dsurfactant; elubricant.  
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(SAB) pH 4.5, water+3% SDS, water+3% polysorbate 
80, water+3% polysorbate 20. Fifty miligrams of soy 
extract were added to 50 mL of each medium. Vessels 
were kept at 37±0.5 °C and stirred at 150 rpm. After 24 
h, 2 mL samples were withdrawn, centrifuged at 1620 
x g, filtered and quantified by HPLC.
 Dissolution profiles for genistein and daidzein 
from different tablets were evaluated by using 900 mL of 
3% SDS aqueous solution in a Varian VK 7000 Dissolution 
Test System (Cary, USA) equipped with paddle apparatus 
(USP Apparatus 2) kept at 37±0.5 °C. Samples were stirred 
at 100 rpm for 120 min and, after that, stirring was raised 
to 150 rpm to reach dissolution infinite point. Samples of 
3 mL were collected at 5, 10, 15, 30, 45, 60, 90, 120 and 
150 min, filtered and quantified by HPLC. All analyses 
were performed under sink conditions (n=6). Data were 
analyzed using ANOVA with p<0.05 as the minimal level 
of significance.
Results and discussion 
 Several studies have reported the quantitation 
of soy isoflavones by HPLC (Apers et al., 2004; César 
et al., 2006; César et al., 2007; Prabhakaran et al., 
2006). The method reported here was adapted from the 
literature and validated in accordance to ICH guidelines. 
The chromatographic conditions employed resulted in 
a faster elution of genistein and daidzein (3.29 and 3.97 
min, respectively) compared to other literature methods 
(Apers et al., 2004; César et al., 2006; César et al., 
2007). Figure 1 illustrates a chromatogram obtained 
for genistein and daidzein quantitation according to 
the analytical method. Tail factor was 1.15 and 1.12 
for genistein and daidzein, respectively. Theoretical 
plate values were above 2000 for both isoflavones, 
demonstrating peak symmetry. The calibration curve 
was linear in the concentration range (1.5-36 μg/mL) 
for both genistein (y=0.0148x-0.0341, r=0.9998) and 
daidzein (y=0.0145x-0.0481, r=0.999). 
 Precision and accuracy were determined from 
solutions at concentrations of 1.5, 15 and 30 μg/mL 
of genistein or daidzein with variation coefficients 
always lower than 5%. Intra- and inter-day precision 
and accuracy of the method for daidzein varied from 
0.58 to 4.68% and 97.27 to 102.44%, respectively. For 
genistein, intra- and inter-day precision and accuracy 
varied from 0.34 to 1.67% and 96.40 to 99.56%, 
respectively. The limit of quantitation for both genistein 
and daidzein was 0.08 μg/mL. The selectivity was 
investigated against tablets components and dissolution 
medium. No interference was observed in the genistein 
and daidzein retention time, indicating the specificity 
of the proposed method (Figure 1). The method was 
validated in accordance to the ICH guidelines (2003).
Figure 1. Chromatogram obtained from the analysis of a 100 
μg/mL dried soy dry extract solution in methanol (11.1% 
genistein and 27.8% daidzein). Mobil phase was methanol 
(0.1% acetic acid): water (0.1% acetic acid): acetonitrile 
64:32:4 (v/v/v), flow rate of 0.7 mL/min, 30 °C, injection 
volume was 10 μL and UV detection at 254 nm.
 The amount of genistein and daidzein in the 
dried soy extract was then determined. Soy extract had 
27.8±1.25% (w/w) of daidzein and 11.1±0.7% (w/w) 
of genistein, slightly different from the information 
given by the manufacturer, as previously reported. The 
glycosides daidizin and genistin were not detected. 
The aglycone concentrations after acidic hydrolysis 
of soy extract were very similar (p>0.05) to the 
concentrations in the hydrolyzed samples (27.5±0.2 % 
for daidzein and 11.0±0.1% for genistein). These small 
differences indicate that the method proposed in this 
study for a fast and reliable determination of genistein 
and daidzein was applicable even without the need for 
a prior hydrolytic step.
Development of solid dosage forms containing dried 
soy extract
 Improving the quality of solid dosage forms 
obtained from plant extracts has been the focus 
of an increasing number of studies, and the use of 
suitable excipients or wet granulation techniques 
has demonstrated great potential in improving the 
performance of these formulations (Gallo et al., 2011). 
Properties of the soy extract in powder or in granular 
forms are shown in Table 2. Pure dried soy extract 
didn’t flow through a 15 mm diameter orifice in the 
GTB flow tester. Carr and Hausner indexes, as well as 
angle of repose values, indicate a high cohesiveness for 
pure dried soy extract, which is an undesirable feature 
for the use in direct compression process (Patra et al., 
2008; Palma et al., 2002). Similarly, the formulation 
designed for direct compression prepared with 50% 
(w/w) of soy extract (DC, Table 2) also resulted in high 
values for Carr and Hausner indexes, denoting still a high 
cohesiveness of the mixture. A slight improvement of 
the flow properties was obtained with this formulation; 
however, the flow rate was still inadequate for the 
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necessary tableting technological parameters.
 Granules prepared by wet granulation 
exhibited a marked improvement in flowability. Table 
2 exhibits the flow properties and scale of flowability 
of the soy extract and its formulations according 
to USP35. Based on the values for angle of repose, 
Carr and Hausner indexes, formulations CROS-SDS 
and CROS-POV presented a better flow performance 
in comparison with the other formulations. It can be 
noticed that the granules with the poorest flow were 
prepared without SDS (granules CROS, Table 2). Most 
of the formulations had water content in the range of 
4.5 to 5.0%. However, formulations prepared without 
SDS (CROS and DC, Table 2) showed a lower level of 
residual water. These findings suggested the influence 
of the surfactant on water uptake and granule density, 
which might interfere in the flow properties of the 
material.
 Table 3 presents data on the characterization 
of tablets obtained according to formulations described 
in Table 1. No significant differences were observed 
in results for average weight, hardness and thickness 
of all tablets. Tablets prepared by direct compression 
showed a higher friability, which was significantly 
different from other formulations, but within the 
pharmacopeial specifications. Differences were also 
observed in the disintegration time of the tablets. 
Tablets containing croscarmellose and prepared without 
SDS showed disintegration times similar to the tablets 
prepared with crospovidone (≈23 min). On the other 
hand, croscarmellose tablets containing SDS showed a 
faster disintegration, probably due to the increase on 
the wetting properties of the tablets due to the presence 
of the surfactant.
 Solubility of genistein and daidzein in water with 
3% of SDS were determined to be 825 μg/mL and 250 
μg/mL, respectively, which allowed for the dissolution 
study to be conducted under sink conditions, defined 
as the media volume at least three times higher than 
the necessary to obtain a saturated solution of the drug 
(Farmacopéia Brasileira, 1988). Tablets obtained in this 
study were prepared with 150 mg of dried soy extract, 
containing 11.1% of genistein and 27.8% of daidzein. Drug 
release assay was conducted with a dissolution medium 
volume of 900 mL, in which the maximum concentration 
of isoflavones would be around 18.5 μg/mL for genistein 
and 46 μg/mL for daidzein. These maximum theoretical 
concentrations are, respectively, 5.4 and 45 times lower 
than the amount dissolved in the media containing SDS, 
ensuring the sink conditions of the assay.
 The in vitro release profiles of genistein and 
daidzein from the different tablet formulations are 
shown in Figure 2. Genistein release (Figure 2a) from 
the tablet prepared with sodium croscarmellose as 
disintegrant (CROS-SDS) was faster than drug release 
from the other formulations in the first 45 min of 
experiment. Daidzein release from CROS-SDS and the 
other formulations was statistically different (p<0.05) 
from 15 to 30 min of the drug release assay. This 
finding is in agreement with disintegration data (Table 
3). The polymeric coating used in this work (HPMC) 
is a water-soluble film-forming agent used for the 
manufacture of immediate-release solid dosage forms. 
There were no differences in the drug dissolution rate 
from coated and non-coated tablets (data not shown). 
The polymeric coat used in this work was intended to 
promote specific benefits such as improving the visual 
qualities of the dosage form, masking unpleasant 
organoleptic properties and easing ingestion of the 
tablets.
 The best mathematical fit for the drug release 
data describes azero order kinetics model and the 
calculated constant rate value (k) was higher for the 
CROS-SDS formulation (Table 4). CROS formulation 
was also prepared with croscarmellose, however, 
its disintegration and genistein release profile were 
similar to the formulations prepared with crospovidone 
and SDS (p>0.05). In spite of this, the k value for 
croscarmellose formulations was higher than the 
calculated k for crospovidone formulations. This 
behavior can be attributed to the lower wetting of the 
CROS tablets due to absence of the surfactant, which 
also increased the disintegration time.
Table 2. Characterization of powder and granules containing soy isoflavone extract.
Material Flow rate (s) Angle of repose (°) Carr index Hausner index Water content (%)
Soy isoflavone extract (powdered form) - - 42.86e 1.75e 4.4±0.2
Granules CROS-SDSa 4.8±0.8 28.4±0.5b 18.68f 1.23f 4.6±0.1
Granules CROSa 6.7±0.9 34.1±1.8c 26.06g 1.35g 2.7±0.2
Granules CROS-POV-10a 4.8±1.1 28.3±1.2b 22.45h 1.29h 5.0±0.1
Granules CROS-POVa 4.5±0.5 27.6±0.9b 16.85f 1.20f 4.9±0.2
DC powdered forma 50.6±2.8 39.2±1.1d 40.00e 1.66e 2.3±0.3
aFormulations from Table 1; low properties and corresponding angles of repose, according to USP 35: bexcellent; cgood; dfair; Scale of flowability 
based on Carr and Hausner indexes, according to USP35: every, very poor; ffair; gpoor; hpassable.
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 The type of crospovidone used did not promote 
changes neither in disintegration nor genistein release 
form soy tablets. Polyplasdone XL and Polyplasdone 
XL-10 differ by the size of the crospovidone particles. 
Polyplasdone XL has a larger particle size (100-130 
μm) and should provide a faster disintegration time 
than Polyplasdone XL-10 (30-50 μm particle size). 
In the present work, the particle size did not alter 
disintegration and in vitro drug release of genistein. 
 The best mathematical fit of daidzein release 
data also described azero order kinetics and exhibited 
the same tendencies observed for genistein. Statistical 
differences between CROS-SDS formulation and the 
other tablets were only seen in the first 30 min of the 
assay.
 The CROS-SDS tablet formulation presented 
the higher k values for genistein and daidzein and 
the release amounts were significantly higher for this 
composition. Based on the characteristics of immediate 
release pharmaceutical tablets, CROS-SDS can be 
considered as the most appropriated formulation in this 
study.
References 
Apers S, Naessens T, Steen KVD, Cuyckens F, Claeys M; 
Pieters L, Vlietinck A 2004. Fast high-performance 
liquid chromatography method for quality control of 
soy extracts. J Chromatogr A 1038: 107-112.
Campos MG, Paranhos AH, Matos MP, Câmara MT, Cunha 
Table 3. Characterization of tablets prepared by wet granulation or direct compression.
Formulation* Average weight (mg)a
Hardness 
(Kgf)a
Thickness 
(mm)a
Disintegration 
(min)b Friability (%)
a
Tablet CROS-SDS 301.5±3.7 9.4±1.5 4.65±0.02 15 0
Tablet CROS 306.8±2.3 8.2±2.1 5.10±0.06 23 0
Tablet CROS-POV-10 298.7±4.6 10.1±1.6 4.59±0.02 23 0
Tablet CROS-POV 301.4±3.3 9.2±0.8 4.67±0.07 24 0
Tablet DC 314.9±15.7 9.1±5.2 5.02±0.23 16 0.5
DC powdered forma 50.6±2.8 39.2±1.1d 40.00e 1.66e 2.3±0.3
aMean±SD of twenty measurements; bMean±SD of six measurements; *Formulation from Table 1.
Table 4. Constant rate (k) values (in mg•mL-1/min) and r2 of zero order kinetic model applied to the different formulations of genistein 
and daidzein.
Formulations
Daidzein Genistein
k values r2 coefficient k values r2 coefficient
CROS 1.487 0.9994 1.672 0.9996
CROS-SDS 1.699 0.9855 1.944 0.9864
CROS-POV 1.084 0.9957 0.820 0.9965
CROS-POV 10 1.301 0.9949 0.699 0.9974
DC 1.058 0.9997 0.815 0.9892
Figure 2. Genistein (A) and daidzein (B) release from different tablets (CROS-SDS, CROS, CROS-POV, CROS-POV 10 and 
CD). *p<0.05.
Preparation and characterization of solid oral dosage forms containing soy 
isoflavones
Stela R. de Oliveira et al.
Rev. Bras. Farmacogn. Braz. J. Pharmacogn. 23(1): Jan./Feb. 2013 181
MM, Pinto P, Silvestre A, Amado F, Neto C 2006. 
Comparative analysis of over the counter tablet 
preparations of isoflavones extracted from soy in 
Portugal. Nat Prod Commun 1: 972-980.
César IC, Braga FC, Soares CDV, Nunan EA, Pianetti GA, 
Condessa FA, Barbosa TAF, Campos LMM 2006. 
Development and validation of a RP-HPLC method for 
quantification of isoflavone aglycones in hydrolyzed 
soy dry extracts. J Chromatogr B 836: 74-78. 
César IC, Braga FC, Vianna-Soares CD, Nunan EA, Barbosa 
TAF, Moreira-Campos LM 2007.  Determinação da 
daidzeína, genisteína e gliciteína em cápsulas de 
isoflavonas por cromatografia em camada delgada 
(CCD) e cromatografia líquida de alta eficiência 
(CLAE). Rev Bras Farmacogn 17: 616-625.
Farmacopéia Brasileira 1988. 4 ed., São Paulo, Atheneu, 
1988. 
Ferrari A 2009. Soy extract phytoestrogens with high dose 
of isoflavones for menopausal symptoms. J Obstet 
Gynaecol Re 35: 1083-1090.
Gallo L, Llabot JM, Allemandi D, Bucalá V, Pinã J 2011. 
Influence of spray-drying operating conditions on 
Rhamnus purshiana (Cáscara sagrada) extract powder 
physical properties. Powder Technol 208: 205-214. 
Howes JB, Sullivan D, Lai N, Nestel P, Pomeroy S, West 
L, Eden JA, Howes LG 2000. The effects of dietary 
supplementation with isoflavones from red clover on 
the lipoprotein profiles of post menopausal women 
with mild to moderate hypercholesterolaemia. 
Atherosclerosis 152: 143-147. 
ICH-Harmonised Tripartite Guidence Q2B 2003. In: 
International Conference on Harmonization 
of Technical requirements for Registration of 
Pharmaceutical for Human Use. 
Prabhakaran MP, Hui LS, Pereira CO 2006. Evalution of 
the composition and concentration of isoflavones in 
soy based supplements, health products and infant 
formulas. Food Res Int 39: 730-738.
Palma S, Lujan C, Llabot JM, Barboza G, Manzo RH, Allemandi 
DA 2002. Design of Peumus boldus tablets by direct 
compression using a novel dry plant extract.  Int J Pharm 
233: 191-198.
Patra CN, Pandit HK, Singh SP, Devi MV 2008. Applicability 
and comparative evaluation of wet granulation 
and direct compression technology to Rauwolfia 
serpentina root powder: a technical note. Aaps Pharm 
Sci Tech 9: 100-104.
Setchell KDR, Brzezinski A, Brown NM, Desai PB, Melhem 
M, Meredith T, Zimmer-Nechimias L, Wolfe B, 
Cohen Y, Blatt Y 2005. Pharmacokinetics of a slow-
release formulation of soybean isoflavones in healthy 
postmenopausal women. J Agric Food Chem 53: 
1938-1944.
Shen Q, Li X, Yuan D, Ji W 2010. Enhanced oral bioavailability 
of daidzein by self-microemulsifying drug delivery 
system. Chem Pharm Bull 58: 639-643. 
Silva MIG, Melo CTV, Vasconcelos LF, Carvalho AMR, Sousa 
FCF 2012. Bioactivity and potential therapeutic benefits 
of some medicinal plants from the Caatinga (semi-arid) 
vegetation of Northeast Brazil: a review of the literature. 
Rev Bras Farmacogn 22: 193-207. 
USP 35/NF 30 2012. United States Pharmacopeia & National 
Formulary. Rockville: United States Pharmacopeial 
Convention. 
*Correspondence
Eliana Martins Lima
Laboratório de Tecnologia Farmacêutica, Faculdade de 
Farmácia, Universidade Federal de Goiás
Praça Universitária, Praça Universitária c/ 1ª. Avenida, Qd. 
62, 74.605-220 Goiânia-GO, Brazil 
emlima@farmacia.ufg.br 
Tel: +55 62 3209 6039
